Evidence map›Paper›PMID 36555328›Full record

ArticleInternational journal of molecular sciences2022

Shrunken Pore Syndrome Is Frequently Occurring in Severe COVID-19.

Anders O Larsson, Michael Hultström, Robert Frithiof, Miklos Lipcsey, Mats B Eriksson

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. A lower eGFRRenal failure · 2024
    Article
  4. eGFRBMC nephrology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 3 countries.

Anders O LarssonDepartment of Medical Sciences, Section of Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-3161-0402
Michael HultströmDepartment of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-4675-1099
Robert FrithiofDepartment of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-2278-7951
Miklos LipcseyDepartment of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-1976-4129
Mats B ErikssonDepartment of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-3178-4210
Uppsala University · SE

Funding

Knut and Alice Wallenberg Foundation KAW 2020.0182, KAW 2020.0241Science for Life Laboratory KAW 2020.0182, KAW 2020.0241Swedish Heart-Lung Foundation 2021089, 20190639, 20190637Swedish Research Council 2014-02569, 2014-07606,The Swedish kidney foundation F2020-0054The Swedish Society of Medicine SLS-938101
6 · The paper itself

Abstract

A selective decrease in the renal filtration of larger molecules is attributed to the shrinkage of glomerular pores, a condition termed Shrunken Pore Syndrome (SPS). SPS is associated with poor long-term prognosis. We studied SPS as a risk marker in a cohort of patients with COVID-19 treated in an intensive care unit. SPS was defined as a ratio < 0.7 when the estimated glomerular filtration rate (eGFR), determined by cystatin C, calculated by the Cystatin C Caucasian-Asian-Pediatric-Adult equation (CAPA), was divided by the eGFR determined by creatinine, calculated by the revised Lund−Malmö creatinine equation (LMR). Clinical data were prospectively collected. In total, SPS was present in 86 (24%) of 352 patients with COVID-19 on ICU admission. Patients with SPS had a higher BMI, Simplified Physiology Score (SAPS3), and had diabetes and/or hypertension more frequently than patients without SPS. Ninety-nine patients in the total cohort were women, 50 of whom had SPS. In dexamethasone-naïve patients, C-reactive protein (CRP ), TNF-alpha, and interleukin-6 did not differ between SPS and non-SPS patients. Demographic factors (gender, BMI) and illness severity (SAPS3) were independent predictors of SPS. Age and dexamethasone treatment did not affect the frequency of SPS after adjustments for age, sex, BMI, and acute severity. SPS is frequent in severely ill COVID-19 patients. Female gender was associated with a higher proportion of SPS. Demographic factors and illness severity were independent predictors of SPS.

Indexed as

COVID-19KidneyCreatinineCystatin CDexamethasoneFemaleGlomerular Filtration RateHumansMaleSyndromeCreatinineCystatin CDexamethasonebiomarkercorticosteroidsCOVID-19 creatininecystatin CeGFRgenderintensive careSARS-CoV-2shrunken pore syndromeSPS

Identifiers

PMID36555328
PMCPMC9779236
OpenAlexW4312123960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.